Royce & Associates LP Regenxbio Inc. Transaction History

Royce & Associates LP

$10.3 Billion
Q2 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	SELL	$16.46 - $19.99 $267,475 - $324,837	-16,250 Reduced 9.79%	149,664 $2.46 Million
Q2 2023 Aug 07, 2023	SELL	$17.23 - $21.71 $284,915 - $358,996	-16,536 Reduced 9.06%	165,914 $3.32 Million
Q1 2023 May 04, 2023	BUY	$18.08 - $24.55 $1.82 Million - $2.48 Million	100,871 Added 123.65%	182,450 $3.45 Million
Q4 2022 May 23, 2023	SELL	$20.4 - $24.73 $2.06 Million - $2.49 Million	-100,871 Reduced 55.29%	81,579 $1.85 Million
Q4 2022 Feb 13, 2023	BUY	$20.4 - $24.73 $1.07 Million - $1.29 Million	52,296 Added 178.59%	81,579 $1.85 Million
Q3 2022 Nov 03, 2022	BUY	$22.29 - $35.04 $284,442 - $447,145	12,761 Added 77.24%	29,283 $774,000
Q2 2022 Aug 04, 2022	BUY	$19.35 - $35.04 $319,700 - $578,930	16,522 New	16,522 $408,000
Q3 2020 Nov 12, 2020	SELL	$27.01 - $40.26 $1.62 Million - $2.42 Million	-60,000 Closed	0 $0
Q2 2019 Aug 12, 2019	BUY	$42.0 - $59.29 $1.32 Million - $1.87 Million	31,539 Added 110.81%	60,000 $3.08 Million
Q1 2019 May 09, 2019	BUY	$40.82 - $62.45 $3,592 - $5,495	88 Added 0.31%	28,461 $1.63 Million
Q4 2018 Feb 11, 2019	BUY	$39.11 - $75.15 $3,598 - $6,913	92 Added 0.33%	28,373 $1.19 Million
Q3 2018 Nov 13, 2018	SELL	$65.0 - $82.15 $775,645 - $980,295	-11,933 Reduced 29.67%	28,281 $2.14 Million
Q2 2018 Aug 09, 2018	SELL	$27.2 - $74.35 $1 Million - $2.74 Million	-36,786 Reduced 47.77%	40,214 $2.89 Million
Q1 2018 May 14, 2018	BUY	$24.05 - $37.5 $432,900 - $675,000	18,000 Added 30.51%	77,000 $2.3 Million
Q4 2017 Feb 09, 2018	BUY	$26.0 - $34.6 $1.53 Million - $2.04 Million	59,000	59,000 $1.96 Million

Others Institutions Holding RGNX

# of Institutions

193

Shares Held

43.5M

Call Options Held

58.9K

Put Options Held

58.4K

View Full List

About REGENXBIO Inc.

Ticker RGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,230,000
Market Cap $404M
Description
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...

More about RGNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Royce & Associates LP, based on Form 13F filings with the SEC.

News

Stay updated on Royce & Associates LP with notifications on news.

Account